サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427693

アルファグルコシダーゼ阻害剤の世界市場レポート 2024

Alpha Glucosidase Inhibitors Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アルファグルコシダーゼ阻害剤の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

アルファグルコシダーゼ阻害剤の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.5%の年間複合成長率（CAGR）で61億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、早期介入、高齢者人口の増加、糖尿病制御を目的とした世界のヘルスケア取り組み、併用療法への統合がますます重視されていることに起因すると考えられます。予測期間中に予想される主な動向には、患者中心のアプローチ、2型糖尿病管理への重点、ドラッグデリバリーにおける技術進歩、新市場の出現、世界化、業界内でのコラボレーションやパートナーシップの増加などが含まれます。

糖尿病の世界の有病率の拡大は、予見可能な将来にアルファグルコシダーゼ阻害剤市場の拡大を大きく推進すると予想されます。血糖値の上昇を特徴とする慢性代謝疾患である糖尿病は、心臓、血管、目、腎臓、神経などのさまざまな身体システムに深刻なリスクをもたらします。アルファグルコシダーゼ阻害剤は、小腸での炭水化物の吸収を阻害することで機能し、食後の血糖値の上昇を効果的に抑制し、糖尿病の管理を助けます。たとえば、2022年 11月の国際糖尿病連盟のデータによると、世界中で5億3,700万人の成人（10人に1人に相当）が糖尿病に苦しんでいます。さらに、世界の糖尿病有病者数は増加し、2030年までに6億4,300万人、2045年までに7億8,300万人に達すると予測されています。したがって、世界の糖尿病罹患率の増加は、アルファグルコシダーゼ阻害剤市場の拡大を促進する重要な原動力となっています。

高齢化に向けた人口動態の拡大は、アルファグルコシダーゼ阻害剤市場の成長を推進する重要な触媒になると予想されます。「高齢化人口」という用語は、社会または人口における高齢者の割合の増加を特徴とする人口動態を意味します。この人口統計セグメントは、血糖値の調節と管理にアルファグルコシダーゼ阻害剤を頻繁に利用しています。これらの薬剤は炭水化物の吸収を遅らせるのに役立ち、高齢者に多い糖尿病の効果的な管理を提供するからです。たとえば、2022年10月に世界保健機関（WHO）が発表したデータは、60歳以上の世界人口が急速に増加し、2050年までに倍増し、推定21億人に達すると予測されていることが浮き彫りになった。その結果、高齢化人口の急増は、アルファグルコシダーゼ阻害剤市場の成長を促進する重要な推進力として機能します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のアルファグルコシダーゼ阻害剤市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ダンピング症候群
  • 2型糖尿病
  • 世界のアルファグルコシダーゼ阻害剤市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アカルボース
  • ミグリトール
  • ヴォグリボース
  • 世界のアルファグルコシダーゼ阻害剤市場、成分別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • グルコアミラーゼ
  • イソマルタス
  • マルターゼ
  • スクラーゼ
  • 世界のアルファグルコシダーゼ阻害剤市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • オンライン薬局
  • 小売薬局
  • 病院薬局

第7章 地域および国の分析

  • 世界のアルファグルコシダーゼ阻害剤市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のアルファグルコシダーゼ阻害剤市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • アルファグルコシダーゼ阻害剤市場の競合情勢
  • アルファグルコシダーゼ阻害剤市場企業プロファイル
    • Pfizer Inc.
    • Roche
    • Bayer AG
    • Novartis AG
    • Sanofi AS

第31章 その他の大手および革新的な企業

  • Bristol Myers Squibb Company
  • AstraZeneca Plc.
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Company
  • Novo Nordisk AS
  • Merck KGaA
  • Sumitomo Chemical Co.Ltd.
  • CH Boehringer Sohn AG and Co. KG
  • Astellas Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals LLC
  • Glenmark Pharmaceuticals Ltd.
  • Biocon
  • Torrent Pharmaceuticals
  • Lotus Pharmaceutical Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13537

Alpha-glucosidase inhibitors constitute a class of medications used in diabetes management. They function by impeding the intestine's absorption of carbohydrates, particularly beneficial for individuals with impaired glucose tolerance to prevent the onset of type 2 diabetes mellitus. These inhibitors offer advantages for those at risk of hypoglycemia or lactic acidosis.

The primary applications of alpha-glucosidase inhibitors include addressing dumping syndrome and managing type 2 diabetes. Dumping syndrome encompasses symptoms resulting from swift gastric emptying after meals, leading to a rapid passage of food from the stomach to the duodenum. This acceleration increases sugar levels, and alpha-glucosidase inhibitors play a crucial role in slowing down food digestion, thereby reducing peak blood glucose concentrations post meals. Notable drug classes in this category include acarbose, miglitol, and voglibose, comprising constituents such as glucoamylase, isomaltase, maltase, and sucrase. These medications are distributed through various channels, including online pharmacies, retail pharmacies, and hospital pharmacies.

The alpha-glucosidase inhibitors market research report is one of a series of new reports from The Business Research Company that provides alpha-glucosidase inhibitors market statistics, including alpha-glucosidase inhibitors industry global market size, regional shares, competitors with an alpha-glucosidase inhibitors market share, detailed alpha-glucosidase inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the alpha-glucosidase inhibitors industry. This alpha-glucosidase inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alpha glucosidase inhibitors market size has grown strongly in recent years. It will grow from $4.22 billion in 2023 to $4.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth observed in the historical period can be attributed to several factors, including a heightened incidence of diabetes, increased awareness of diabetes management, advancements in strategies for treating diabetes, a preference for oral antidiabetic medications, and the influence of clinical research promoting evidence-based medicine.

The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.11 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the forecast period can be attributed to an increasing emphasis on early intervention, a growing geriatric population, global healthcare initiatives aimed at diabetes control, and integration into combination therapies. Major trends expected in the forecast period include patient-centric approaches, a focus on type 2 diabetes management, technological advancements in drug delivery, the emergence of new markets, and globalization, as well as increased collaborations and partnerships within the industry.

The escalating global prevalence of diabetes is anticipated to significantly drive the expansion of the alpha-glucosidase inhibitors market in the foreseeable future. Diabetes, a chronic metabolic condition characterized by elevated blood glucose levels, poses severe risks to various bodily systems, including the heart, blood vessels, eyes, kidneys, and nerves. Alpha-glucosidase inhibitors function by impeding carbohydrate absorption in the small intestine, effectively curbing the surge in postprandial blood glucose levels and aiding in diabetes management. For instance, data from the International Diabetes Federation in November 2022 reported that globally, 537 million adults (equating to 1 in 10 individuals) were afflicted by diabetes. Additionally, projections indicate an anticipated increase in global diabetes prevalence, reaching 643 million by 2030 and 783 million by 2045. Hence, the mounting global incidence of diabetes stands as a key driver fueling the expansion of the alpha-glucosidase inhibitors market.

The expanding demographic shift towards an aging population is anticipated to be a significant catalyst propelling the growth of the alpha-glucosidase inhibitors market. The term 'aging population' signifies a demographic trend characterized by an increasing proportion of elderly individuals within a society or populace. This demographic segment frequently utilizes alpha-glucosidase inhibitors to regulate and manage blood glucose levels, as these medications aid in slowing carbohydrate absorption, offering effective diabetes management-a condition prevalent among older individuals. For instance, data from the World Health Organization (WHO) in October 2022 highlighted a swift rise in the global population of individuals aged 60 years and older, projected to double by 2050, reaching an estimated 2.1 billion individuals. Consequently, the burgeoning aging population serves as a significant driver in fostering growth within the alpha-glucosidase inhibitors market.

A burgeoning trend within the alpha-glucosidase inhibitors market revolves around robust product innovation. Major players in this domain are fervently engaged in pioneering novel products to fortify their market stance. A striking example of this trend emerged in January 2023 when TheracosBio, a distinguished pharmaceutical entity based in the United States, garnered approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin). This innovative oral medication operates as an inhibitor of sodium-glucose cotransporter 2 (SGLT2), specifically tailored for adults grappling with type 2 diabetes. Brenzavvy stands as an adjunct to dietary and exercise regimens, functioning by prompting the kidneys to expel sugar through urine, thereby aiding individuals with type 2 diabetes in effectively managing their blood sugar levels.

Strategic product advancements remains a pivotal strategy adopted by major contenders within the alpha-glucosidase inhibitors market. These companies are diligently crafting inventive solutions such as acarbose tablets to fortify their market foothold. Notably, acarbose stands as an established alpha-glucosidase inhibitor instrumental in the management of type-2 diabetes. In March 2022, Shandong Lukang Pharmaceutical Co. Ltd., an esteemed pharmaceutical entity headquartered in China, unveiled its acarbose tablet in the targeted market. Designed to complement dietary control and exercise programs, these tablets offer significant benefits for individuals coping with type 2 diabetes. Furthermore, they aid in curbing postprandial blood glucose levels in patients afflicted with impaired glucose tolerance, serving as a pivotal addition to the array of treatments available for such conditions.

In April 2023, the pharmaceutical company Sanofi S.A., based in France, successfully acquired Provention Bio Inc. for an undisclosed amount. This strategic move is aimed at broadening Sanofi's diabetes drug portfolio by incorporating TZIELD (teplizumab-mzwv), an innovative and fully owned first-in-class therapy designed for type 1 diabetes. Provention Bio Inc., based in the United States, is recognized for its expertise in the development of diabetes drugs.

Major companies operating in the alpha glucosidase inhibitors market report are Pfizer Inc., Roche, Bayer AG, Novartis AG, Sanofi AS, Bristol Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Novo Nordisk AS, Merck KGaA, Sumitomo Chemical Co. Ltd., C. H. Boehringer Sohn AG and Co. KG, Astellas Pharma, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Biocon, Torrent Pharmaceuticals, Lotus Pharmaceutical Co. Ltd., Anderson Hay and Grain Co. Inc., BioVision Inc., Border Valley Trading, Straight Healthcare, Synjardi XR

North America was the largest region in the alpha glucosidase inhibitors market in 2023. Middle-East is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha glucosidase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the alpha glucosidase inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The alpha-glucosidase inhibitors market consists of sales of glucobay and triazolo quinazolines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Alpha Glucosidase Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alpha glucosidase inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alpha glucosidase inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The alpha glucosidase inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Dumping Syndrome; Type 2 Diabetes
  • 2) By Drug class: Acarbose; Miglitol; Voglibose
  • 3) By Constituent: Glucoamylase; Isomaltase; Maltase; Sucrase
  • 4) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Hospital Pharmacies
  • Companies Mentioned: Pfizer Inc.; Roche; Bayer AG; Novartis AG; Sanofi AS
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Alpha Glucosidase Inhibitors Market Characteristics

3. Alpha Glucosidase Inhibitors Market Trends And Strategies

4. Alpha Glucosidase Inhibitors Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Alpha Glucosidase Inhibitors Market Size and Growth

  • 5.1. Global Alpha Glucosidase Inhibitors Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Alpha Glucosidase Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Alpha Glucosidase Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Alpha Glucosidase Inhibitors Market Segmentation

  • 6.1. Global Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Dumping Syndrome
  • Type 2 Diabetes
  • 6.2. Global Alpha Glucosidase Inhibitors Market, Segmentation By Drug class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Acarbose
  • Miglitol
  • Voglibose
  • 6.3. Global Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Glucoamylase
  • Isomaltas
  • Maltase
  • Sucrase
  • 6.4. Global Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

7. Alpha Glucosidase Inhibitors Market Regional And Country Analysis

  • 7.1. Global Alpha Glucosidase Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Alpha Glucosidase Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Alpha Glucosidase Inhibitors Market

  • 8.1. Asia-Pacific Alpha Glucosidase Inhibitors Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Alpha Glucosidase Inhibitors Market

  • 9.1. China Alpha Glucosidase Inhibitors Market Overview
  • 9.2. China Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Alpha Glucosidase Inhibitors Market

  • 10.1. India Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Alpha Glucosidase Inhibitors Market

  • 11.1. Japan Alpha Glucosidase Inhibitors Market Overview
  • 11.2. Japan Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Alpha Glucosidase Inhibitors Market

  • 12.1. Australia Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Alpha Glucosidase Inhibitors Market

  • 13.1. Indonesia Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Alpha Glucosidase Inhibitors Market

  • 14.1. South Korea Alpha Glucosidase Inhibitors Market Overview
  • 14.2. South Korea Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Alpha Glucosidase Inhibitors Market

  • 15.1. Western Europe Alpha Glucosidase Inhibitors Market Overview
  • 15.2. Western Europe Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Alpha Glucosidase Inhibitors Market

  • 16.1. UK Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Alpha Glucosidase Inhibitors Market

  • 17.1. Germany Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Alpha Glucosidase Inhibitors Market

  • 18.1. France Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Alpha Glucosidase Inhibitors Market

  • 19.1. Italy Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Alpha Glucosidase Inhibitors Market

  • 20.1. Spain Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Alpha Glucosidase Inhibitors Market

  • 21.1. Eastern Europe Alpha Glucosidase Inhibitors Market Overview
  • 21.2. Eastern Europe Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Alpha Glucosidase Inhibitors Market

  • 22.1. Russia Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Alpha Glucosidase Inhibitors Market

  • 23.1. North America Alpha Glucosidase Inhibitors Market Overview
  • 23.2. North America Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Alpha Glucosidase Inhibitors Market

  • 24.1. USA Alpha Glucosidase Inhibitors Market Overview
  • 24.2. USA Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Alpha Glucosidase Inhibitors Market

  • 25.1. Canada Alpha Glucosidase Inhibitors Market Overview
  • 25.2. Canada Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Alpha Glucosidase Inhibitors Market

  • 26.1. South America Alpha Glucosidase Inhibitors Market Overview
  • 26.2. South America Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Alpha Glucosidase Inhibitors Market

  • 27.1. Brazil Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Alpha Glucosidase Inhibitors Market

  • 28.1. Middle East Alpha Glucosidase Inhibitors Market Overview
  • 28.2. Middle East Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Alpha Glucosidase Inhibitors Market

  • 29.1. Africa Alpha Glucosidase Inhibitors Market Overview
  • 29.2. Africa Alpha Glucosidase Inhibitors Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Alpha Glucosidase Inhibitors Market, Segmentation By Constituent, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Alpha Glucosidase Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Alpha Glucosidase Inhibitors Market Competitive Landscape And Company Profiles

  • 30.1. Alpha Glucosidase Inhibitors Market Competitive Landscape
  • 30.2. Alpha Glucosidase Inhibitors Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Roche
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bayer AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi AS
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Alpha Glucosidase Inhibitors Market Other Major And Innovative Companies

  • 31.1. Bristol Myers Squibb Company
  • 31.2. AstraZeneca Plc.
  • 31.3. Takeda Pharmaceutical Co. Ltd.
  • 31.4. Eli Lilly and Company
  • 31.5. Novo Nordisk AS
  • 31.6. Merck KGaA
  • 31.7. Sumitomo Chemical Co.Ltd.
  • 31.8. C. H. Boehringer Sohn AG and Co. KG
  • 31.9. Astellas Pharma
  • 31.10. Sun Pharmaceutical Industries Ltd.
  • 31.11. Amneal Pharmaceuticals LLC
  • 31.12. Glenmark Pharmaceuticals Ltd.
  • 31.13. Biocon
  • 31.14. Torrent Pharmaceuticals
  • 31.15. Lotus Pharmaceutical Co. Ltd.

32. Global Alpha Glucosidase Inhibitors Market Competitive Benchmarking

33. Global Alpha Glucosidase Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Alpha Glucosidase Inhibitors Market

35. Alpha Glucosidase Inhibitors Market Future Outlook and Potential Analysis

  • 35.1 Alpha Glucosidase Inhibitors Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Alpha Glucosidase Inhibitors Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Alpha Glucosidase Inhibitors Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer